# What are the restrictions on prescribing for patients with non-acute porphyria?

Prepared by UK Medicines Information ([UKMi](http://www.ukmi.nhs.uk/ukmi/about/default.asp?pageRef=1)) pharmacists for NHS healthcare professionals

Before using this Q&A, read the disclaimer at [*https://www.sps.nhs.uk/articles/about-ukmi-medicines-qas/*](https://www.sps.nhs.uk/articles/about-ukmi-medicines-qas/)

Date prepared: 2 December 2019

## Background

The porphyrias can be split into two types according to whether they cause acute attacks or whether they have mainly skin effects. This advice is intended for patients with non-acute porphyria (congenital erythropoietic porphyria, erythropoietic protoporphyria or porphyria cutanea tarda). Patients with non-acute porphyria do not experience acute attacks. Skin lesions develop in these patients when porphyrins accumulate in their skin, absorb energy from the sun and release it, allowing it to damage lower layers of skin (1).

## Answer

### Erythropoietic protoporphyria and congenital erythropoietic porphyria

If patients have unequivocally been diagnosed as having congenital erythropoietic porphyria (CEP) or erythropoietic protoporphyria (EPP), there are **NO UNSAFE DRUGS** (1).

### Porphyria cutanea tarda

In **active** porphyria cutanea tarda (active skin lesions associated with increased circulating plasma porphyrins), all drugs are considered to be **SAFE.**

However caution should be exercised when using:

* High-dose chloroquine (2) or hydroxychloroquine (3)

Chloroquine mobilises porphyrins from the liver (2), allowing them to be excreted in the urine (4). Chloroquine phosphate 125mg to 250mg twice weekly is therefore given as a treatment for active porphyria cutanea tarda (4,5). Hydroxychloroquine 200mg twice weekly has also been used to treat porphyria cutanea tarda but the resulting remission is shorter than with chloroquine (5).

In active porphyria cutanea tarda, it is not recommended that high doses of chloroquine or hydroxychloroquine are given (e.g. chloroquine phosphate 500mg once weekly for the prophylaxis of malaria). The rapid mobilisation of porphyrins from the liver that may be caused by high-dose chloroquine can lead to acute hepatitis (6). Once active porphyria cutanea tarda has been treated and urine porphyrin excretion has returned to normal (i.e. patient is in remission), the patient can be given malaria prophylaxis safely (7).

* Oestrogens

As oestrogens have been implicated in the pathogenesis of porphyria cutanea tarda (2), they should be avoided in patients with active porphyria cutanea tarda. If hormone replacement therapy is strongly indicated, treatment with oestrogens can be prescribed when a patient with porphyria cutanea tarda is in remission (2).

## Summary

* Non-acute porphyrias include congenital erythropoietic porphyria, erythropoietic protoporphyria and porphyria cutanea tarda.
* If a person has an unequivocal diagnosis of congenital erythropoietic porphyria or erythropoietic protoporphyria, all drugs are considered to be safe.
* If a person has been diagnosed with porphyria cutanea tarda, all drugs are considered to be safe excepting oestrogens and high-dose chloroquine or hydroxychloroquine when the porphyria is active.

LimitationsPorphyria cutanea tarda can be precipitated by a number of factors including hepatic iron overload, significant alcohol use, oestrogen exposure (e.g. initiating treatment with hormone replacement therapy or in males, as treatment for prostate cancer), viral infections (such as hepatitis C and HIV), chemical toxicity, liver dysfunction and systemic conditions such as systemic lupus erythematosus and lymphoma (2). It is important to determine how the illness has been acquired. There are individual case reports of porphyria cutanea tarda presenting in patients taking methotrexate (8), pravastatin (9), olmesartan (10), carbamazepine (11) and tamoxifen (12-13), which has partial oestrogenic activity. It has also been reported during post-marketing experience with ofatumumab (14). However, there is insufficient evidence to suggest that these drugs should be avoided by patients with porphyria cutanea tarda. Advice should be sought from a Porphyria Specialist before stopping the patient’s medication. Further information on the safety of medicines in non-acute porphyria can be obtained from the UK Porphyria Medicines Information Service (UKPMIS); Tel: 029 21842251or at: <https://www.wmic.wales.nhs.uk/specialist-services/drugs-in-porphyria/>.

### References

1. European Porphyria Network. For Patients and Families [cited 2019 Nov 18]. Available from: <http://porphyria.eu/en/content/introduction-porphyria>
2. Porphyria South Africa. Porphyria cutanea tarda [cited 2019 Nov 22]. Available from: <http://www.porphyria-professionals.uct.ac.za/ppb/porphyrias/about-pct>
3. Singal AK, Kormos-Hallberg C, Lee C et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol 2012;10(12): 1402-9.
4. Badminton MN and Elder GH. Management of acute and cutaneous porphyrias. Int J Clin Pract 2002;56(4):272-78.
5. Sarkany RPE. The management of porphyria cutanea tarda. Clin Exptl Dermatol 2001;26:225-32.
6. Bloom M. Porphyria cutanea tarda treated with chloroquine phosphate. Arch Dermatol 1969;100:375-6.
7. Personal communication. Dr M Badminton. Honorary Consultant and Clinical Lead, National Acute Porphyria Service (Cardiff), University Hospital of Wales (2014 Aug 8 and Nov 6).
8. O’Neill T, Simpson J, Smyth SJ, et al. Porphyria cutanea tarda associated with methotrexate therapy. Br J Rheumatol 1993;32(5):411-2.
9. Schindl A, Trautinger F, Pernerstorfer-Schon H, et al. Porphyria cutanea tarda induced by the use of pravastatin. Arch Dermatol 1998;134(10):1305-6.
10. Mas-Vidal A, Coto-Segura P, Garcia-Varona A, et al. Porphyria cutanea tarda induced by olmesartan. J Eur Acad Dermatol Venereol 2010;24(8):977-8.
11. Leo RF and Cannuli AR. Porphyria cutanea tarda associated with carbamazepine treatment. Am J Psych 1996;153(3):443-4.
12. De Boulle M, Vroman P, De Boulle K. Tamoxifen-induced porphyria cutanea tarda. Ned Tijdschr Geneeskd 2013;69(19):941-4.
13. Agarwal R, Peters TJ, Coombes RC, et al. Tamoxifen-related porphyria cutanea tarda. Med Oncol 2002;19(2):121-3.
14. Ofatumumab. In DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA [cited 2019 Nov 25]. Available from: <http://micromedexsolutions.com/>

## Quality Assurance

### Prepared by

Rebecca Wong, Welsh Medicines Information Centre, University Hospital of Wales (Based on previous work by Alex Bailey, Welsh Medicines Information Centre, University Hospital of Wales)

### Date Prepared

2 December 2019

Checked byGail Woodland, Welsh Medicines Information Centre, University Hospital of Wales

### Date of check13 December 2019

### Acknowledgements

We would like to thank Dr Mike Badminton, Honorary Consultant and Clinical Lead, National Acute Porphyria Service (Cardiff), University Hospital of Wales, for his comments.

### Search strategy

1. Embase (porphyria cutanea tarda/dm, pc, th OR erythropoietic protoporphyria/dm, pc, th OR congenital erythropoietic porphyria/dm, pc, th)
2. Medline (PubMed: "porphyria cutanea tarda" OR "erythropoietic protoporphyria" OR "congenital erythropoietic porphyria" AND (prevention OR management))
3. In-house database/ resources (“cutanea tarda” (title) "erythropoietic protoporphyria" (title) OR “congenital erythropoietic porphyria” (title))
4. Micromedex (Congenital erythropoietic porphyria; Erythropoietic protoporphyria; Porphyria cutanea tarda, Drugs that cause porphyria cutanea tarda)
5. NICE Evidence (Porphyria cutanea tarda; Erythropoietic protoporphyria; Congenital erythropoietic porphyria)
6. Internet Search (Google; non-acute porphyria drug administration)